NEW YORK, June 23, 2011 /PRNewswire/ — OTC Markets
Group Inc. (OTCQX: OTCM), the company that operates the world’s
largest electronic marketplace for broker-dealers to trade unlisted
stocks, today announced that Radient
Pharmaceuticals Corporation (OTCQX: RXPC), the developer and
worldwide marketer of the Onko-Sure® non-invasive cancer blood
test kit, has qualified to trade on the OTC market’s highest tier,
OTCQX®.
(Logo:
http://photos.prnewswire.com/prnh/20110118/MM31963LOGO)
“Radient Pharmaceuticals has chosen to remain investor-focused
as they transition to trade on OTCQX, which allows them to continue
to provide superior information and transparent trading on the
quality-controlled OTCQX platform,” said R. Cromwell Coulson,
President and Chief Executive Officer of OTC Markets Group. “We are
pleased to welcome Radient Pharmaceuticals to OTCQX.”
Radient Pharmaceuticals began trading today on the OTC market’s
prestigious tier, OTCQX U.S. Premier. Investors can find current
financial disclosure and Real-Time Level 2 quotes for the Company
on www.otcqx.com and www.otcmarkets.com.
“In moving to OTCQX, we will continue to deliver liquidity,
transparency, and an efficient market for our shareholders while
reducing the financial and management resources required for an
exchange listing,” Douglas MacLellan, CEO of Radient
Pharmaceuticals. “We are moving forward, dedicating more time and
resources to the execution of our core business delivering
high-value cancer diagnostics to the global healthcare system.”
Merriman Capital, Inc. will serve as Radient Pharmaceuticals’
Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for
providing guidance on OTCQX requirements.
About Radient Pharmaceuticals
<
‘/>”/>
SOURCE
